Navigation Links
New drug improves progression-free survival, shrinks tumors in rare cancer for first time
Date:6/1/2013

CHICAGO, JUNE 1, 2013 The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology (ASCO).

The findings are potentially practice-changing for a historically "untreatable disease." Though uveal melanoma is rare there are only 2,500 cases diagnosed in the United States each year about half of patients will develop metastatic disease, and survival for patients with advanced disease has held steady at nine months to a year for decades.

Researchers found that progression-free survival (PFS) in patients receiving selumetinib was nearly 16 weeks and 50 percent of these patients experienced tumor shrinkage, with 15 percent achieving major shrinkage. Patients receiving temozolomide, the current standard chemotherapy, had seven weeks of PFS and no tumor shrinkage. Selumetinib also lengthened overall survival to 10.8 months versus 9.4 months with temozolomide, and side effects were manageable.

"This is the first study to show that a systemic therapy provides significant clinical benefit in a randomized fashion to advanced uveal melanoma patients, who have very limited treatment options," said Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering and lead author on the study. "This clinical benefit has never been demonstrated with other conventional or investigational agents, which is all we have been able to offer patients for decades."

Dr. Carvajal and his team decided to test selumetinib because it blocks the MEK protein, a key component of the tumor-driving MAPK pathway. This pathway is activated by mutations in the Gnaq and Gna11 genes, which occur in more than 85 percent of uveal melanoma patients; 84 percent of patients in this trial had one of the mu
'/>"/>

Contact: Caitlin Hool
hoolc@mskcc.org
646-227-3956
Memorial Sloan-Kettering Cancer Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Lifeguard Master Improves on its Swim Suite Line
2. Task master: Categorizing rewards improves motivation
3. Study shows longer treatment for children with langerhans cell hystiocytosis improves survival rates
4. Levosimendan improves event free survival by 50 percent in end-stage heart failure
5. New Attendance, Vacation and Training Tracker Board Reduces Employee Conflicts and Improves Attendance
6. New smartphone application improves colonoscopy preparation
7. Cognitive training improves executive function in breast cancer survivors
8. Study Shows Dual Targeting of HER2 and HR-positive Metastatic Breast Cancer Improves Survival Rates
9. North Shore-LIJ's New Image Fusion-Guided Biopsy Improves Accuracy of Prostate Cancer Diagnosis
10. Carnegie Mellon Research shows self-affirmation improves problem-solving under stress
11. How Weight-Loss Surgery Improves Diabetes Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Royal Sport Ultra Clean 100 is the ... of premium sports nutrition products. Its gluten free formula ... without artificial colors or dyes, fillers, added sugar and ... shelves at select GNC retailers, on GNC.com, and through ... a limited time special on its products. Customers can ...
(Date:9/23/2014)... ADOMANI, Inc. has announced that ... CEO. He is a 13-year veteran in the school, commercial ... of A-Z Bus Sales of Colton, California. While with A-Z ... their top line revenues, profit and market penetration by double ... diesel to all-electric or plug-in hybrid vehicle conversions. They ...
(Date:9/23/2014)... 23, 2014 Airbus Helicopters Inc. (AHI) ... honored as the 2014 Vision Zero Aviation Safety ... database, a free flight safety service the company ... Manager - Air Medical Specialist for Airbus Helicopters Inc., ... $10,000 check during the Air Medical Transport Conference Annual ...
(Date:9/23/2014)... issue of the European Journal of Cancer ... presented during the 1st EORTC Cancer Survivorship Summit held ... targeted therapeutics, and more personalized multimodal treatments has boosted ... a large and rapidly increasing number of cancer survivors. ... with a broad spectrum of late adverse treatment effects ...
(Date:9/23/2014)... a driving force behind many chronic diseases, especially ... inflammation caused by conditions such as viral hepatitis ... options. Now, scientists at Virginia Commonwealth University Massey ... in preclinical studies that blocking the expression of ... halts the development and progression of liver cancer ...
Breaking Medicine News(10 mins):Health News:Sports Nutrition Brand, Royal Sport LTD, Introduces 'Clean,' Gluten Free Protein Supplement, Royal Sport Ultra Clean 100™ 2Health News:ADOMANI Announces Jim Reynolds to Take Over as President and CEO 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 3Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 4Health News:Study uncovers genetic driver of inflammation, uses it to prevent and treat liver cancer 2
... the major arterial blood vessels. It is one of the ... IL-1 has been linked to atherosclerosis and a clinical trial ... is being studied for its effects on the severe clinical ... a team of researchers led by Gary Owens, at the ...
... By Steven Reinberg HealthDay Reporter , MONDAY, ... may see their IQ improve, Norwegian researchers have found. ... earlier studies did not rule out the possibility that people ... education than others, the researchers noted. Now, however, ...
... like regular schedules for meal, bath, and bed times ... with oral and tactile sensitivities, such as discomfort at ... rituals could be an early warning sign of adult ... Reuven Dar of Tel Aviv University,s Department of Psychology, ...
... Teens are more likely to be obese if they had ... toddlers, according to a new study. The findings echo ... ties with their parents were more likely to be obese ... the latest study, researchers examined U.S. National Institute of Child ...
... News) -- Being hospitalized during the holidays can be emotionally ... spirits up, experts say. "While the psychological impact ... be well and home than sick and away," Joshua Klapow, ... (UAB), explained in a university news release. "The ...
... A global team of neuroscientists, led by researchers at ... for a brain disorder that may be much more common ... Nature Genetics , the researchers say they ... to development of hereditary diffuse leukoencephalopathy with spheroids ...
Cached Medicine News:Health News:More Schooling Might Raise IQ 2Health News:More Schooling Might Raise IQ 3Health News:Childhood hypersensitivity linked to OCD 2Health News:Mother-Toddler Bond May Influence Teen Obesity 2Health News:A Visit Can Bring Holiday Cheer to Hospitalized Patients 2Health News:'Rare' brain disorder may be more common than thought, say Mayo Clinic scientists 2Health News:'Rare' brain disorder may be more common than thought, say Mayo Clinic scientists 3
(Date:9/23/2014)... September 23, 2014 Avillion ... the appointment of Jarrod Longcor as ... is responsible for structuring, negotiating and executing successful ... well as providing management and strategic leadership to ... Executive leadership team. Mr Longcor brings ...
(Date:9/22/2014)... , September 23, 2014 , ... health authorities, increasing rigor for trial master file (TMF) ... industry,s largest TMF survey to date reveals an increase ... to provide auditors with remote access to their electronic ... owners surveyed in the Veeva 2014 Paperless ...
(Date:9/22/2014)... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ... $200 million of its common stock in an underwritten ... Merrill Lynch are acting as joint book-running managers for ... option to purchase additional shares of its common stock. ... offering are being sold by Avanir.  The offering is ...
Breaking Medicine Technology:Avillion Appoints Jarrod Longcor as Chief Business Officer 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 2Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 3Remote eTMF Access to Double in 2015, Reveals Industry-wide Survey 4Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
... March 15 URL Pharma, Inc. today announced the launch of an expanded ... eligible for low-cost Colcrys therapy. Uninsured and Medicare Part D patients with household incomes ... Colcrys PAP. This expanded program is available to patients immediately. , ... ...
... , March 15 Watson Pharmaceuticals, Inc. ... subsidiary, Watson Laboratories, Inc. – Florida , has ... (FDA) for its Abbreviated New Drug Application (ANDA) for ... Laboratories International SRL,s Cardizem® LA product.  Watson intends to ...
Cached Medicine Technology:URL Pharma Expands Colcrys(R) Patient Assistance Program 2URL Pharma Expands Colcrys(R) Patient Assistance Program 3URL Pharma Expands Colcrys(R) Patient Assistance Program 4URL Pharma Expands Colcrys(R) Patient Assistance Program 5URL Pharma Expands Colcrys(R) Patient Assistance Program 6Watson Receives FDA Approval for Generic Cardizem(R) LA 2Watson Receives FDA Approval for Generic Cardizem(R) LA 3
DS 7600 Central Station...
... MedSystem III DLE (Drug List Editor) Multi-Channel ... drug infusion technology. The instrument combines three ... clinical versatility in an unparalleled small size. ... MedSystem III Infusion System simplifies the delivery ...
... Freedom Chart Manager provides powerful workflow tools ... management, integrated transcription services, and customized flow ... that eliminates the need for paper charts. ... of a paperless office now and can ...
... ChartingPlus proves itself to over 2,000 ... Designed with the user in mind, ChartingPlus ... powerful and dynamic features to improve documentation ... practice. Our medical content is ...
Medicine Products: